Omicia, Inc., a San Francisco Bay Area-based analytical genome interpretation company, closed $6.8m Series A financing.
The round was led by Artis Ventures, with participation from Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital. In conjunction with the funding, Tad Buchanan, principal of Buchanan Investments, and William Gerber, MD, with Bay City Capital, joined the company’s board.
The company intends to use the funds to expand its marketing reach and further optimize its big data genomics offerings.
Led by Mike Aicher, CEO, Omicia develops integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications.
The company launched its cloud-based genome interpretation platform (Opal) in 2012 after extensive beta testing with Stanford University, the University of Utah, ARUP Laboratories, J. Craig Venter Institute, and UC San Francisco. It allows researchers to collaboratively analyze genomes by prioritizing disease-causing variants and genes. The platform also features analytic tools and workflows that help users go beyond variant filtering and perform complex analysis.